CDRE vs GE
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CDRE exhibits a strong deterministic health profile with a Piotroski F-Score of 7/9 and excellent liquidity (Current Ratio 3.50), yet it faces severe valuation and growth headwinds. The stock is trading at a significant premium to its Graham Number ($13.15) and Intrinsic Value ($7.14), while simultaneously experiencing negative YoY revenue (-5.00%) and earnings growth (-13.30%). This fundamental deterioration is compounded by aggressive insider selling totaling $61.87M by the CEO, CFO, and President. Despite a 'strong_buy' analyst consensus, the technical trend is 0/100 and the price is hovering near its 52-week low, suggesting a disconnect between analyst targets and market reality.
GE Aerospace exhibits a stark divergence between its operational growth and its deterministic financial health, highlighted by a weak Piotroski F-Score of 3/9. While the company delivers impressive earnings growth (37.4% YoY) and high ROE (44.69%), it trades at a significant premium to both its Graham Number ($56.79) and Intrinsic Value ($237.48). The valuation is stretched with a PEG ratio of 5.24, suggesting that current price levels have priced in aggressive future success. Despite strong analyst 'strong_buy' recommendations, the combination of poor deterministic health and bearish insider activity warrants a cautious approach.
Compare Another Pair
Related Comparisons
CDRE vs GE: Head-to-Head Comparison
This page compares Cadre Holdings, Inc. (CDRE) and GE Aerospace (GE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.